

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB	3235-			
Number:	0104			
Estimated average				
burden hours p				
response	0.5			

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)					
1. Name and Address of Reporting Person [*] F.C.P.R. Genavent	Statement (Month/Day/Year)	ng 3. Issuer Name and Ticker or Trading Symbol SCYNEXIS INC [SCYX]			ling Symbol
(Last) (First) (Middle) 47 AVENUE DE L'OPERA	05/02/2014	4. Relationship of Reporting Person(s) to Issuer			5. If Amendment, Date Original Filed(Month/Day/Year)
(Street) PARIS CEDEX 07, I0 75002		(Check all applicable) Director _X_10% Owner Officer (give Other (specify title below) below)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip)	Table I - N	on-Derivati	ve Securitie	s Ben	eficially Owned
1.Title of Security (Instr. 4)	2. Amount of Beneficially (Instr. 4)	Owned	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Owner	1

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	Expiration Date		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5.	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Common Stock Warrant (right to buy)	12/07/2011	12/06/2016	Common Stock	5,251	\$ 0.2	D	
Common Stock Warrant (right to buy)	05/15/2012	05/14/2017	Common Stock	5,251	\$ 0.2	D	
Common Stock Warrant (right to buy)	12/11/2013	12/10/2018	Common Stock	3,501	\$ 0.2	D	
Series B Preferred Stock	08/25/2000	<u>(1)</u>	Common Stock	53,112 <u>(1)</u>	\$ <u>(1)</u>	D	
Series C Preferred Stock	06/19/2002	<u>(2)</u>	Common Stock	96,921 <u>(1)</u>	\$ <u>(2)</u>	D	
Series D-1 Preferred Stock	12/11/2013	<u>(3)</u>	Common Stock	46,824 <u>(1)</u>	\$ <u>(3)</u>	D	
Series D-2 Preferred Stock	12/11/2013	<u>(4)</u>	Common Stock	16,738 (1)	\$ <u>(4)</u>	D	

Reporting Owners

Penerting Owner Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
F.C.P.R. Genavent 47 AVENUE DE L'OPERA PARIS CEDEX 07, 10 75002		Х				

Signatures

By: /s/ STANISLAS CUNY, Manager	05/02/2014
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each of the Series B Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-3.536 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
- (2) Each of the Series C Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-3.536 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
- (3) Each of the Series D-1 Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-20.4 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
- (4) Each of the Series D-2 Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-20.4 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.